News
NICE recommends the use of Opdivo in resected oesophageal or gastro-oesophageal junction cancer.
The UK's National Institute for Health and Care Excellence (NICE) has recommended Opdivo (nivolumab), from Bristol Myers Squibb, as a treatment for certain resected oesophageal or gastro-oesophageal junction (GEJ) patients.
In July 2021 Opdivo was cleared as an adjuvant treatment of completely resected oesophageal or GEJ cancer in adults who have residual disease following neoadjuvant chemoradiotherapy.
The new recommendation is based on data showing that Opdivo increases the time patients are able to live without their cancer returning compared to placebo, in patients who had residual disease after chemo or radiotherapy and after surgical intervention.
Condition: Gastric /Junction/Esophageal Adenocarcinoma
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins